Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older

NCT00958126 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT00958126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00958126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older
Lead sponsor
Seqirus
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2009
Completion date
April 30, 2010
Enrollment
1,313 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

influenza